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Purpose: To quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival
epithelial cells collected from Sjogren’s syndrome (SS), non-Sjogren’s keratoconjunctivitus sicca (KCS) and non-dry
eyed (NDE) control subjects.
Methods: Seventy-six subjects were recruited for this study: 25 SS (confirmed via American-European Consensus Criteria
2002), 25 KCS (confirmed by symptoms and Schirmer scores ≤10 mm) and 26 NDE. Tears were collected using an eye-
wash technique. Impression cytology was used to gather protein and mRNA from conjunctival epithelial cells. Soluble
and membrane bound MUC1 were quantified via western blotting and MUC1 mRNA was quantified by real time qPCR.
Results: The SS group demonstrated significantly higher concentrations of soluble MUC1 (0.12±0.11 [SS]; 0.013±0.02
[KCS; p=0.001]; 0.0023±0.0024 [NDE; p<0.001]) and MUC1 mRNA (3.18±1.44 [SS]; 1.79±1.18 [KCS; p<0.05];
1.60±0.74 [NDE; p<0.05]) compared to both KCS and NDE groups. Soluble MUC1 expression was also higher in the
KCS group compared to the NDE group (p=0.02), where as MUC1 mRNA expression was similar in both KCS and NDE
groups.  Membrane  bound  MUC1  expression  differed  only  between  the  SS  and  NDE  groups  (0.005±-0.003  [SS];
0.003±0.002 [NDE; p=0.002]).
Conclusions: These results demonstrate that SS subjects express greater quantities of MUC1 protein and mRNA compared
to both KCS and control subjects. Increased soluble MUC1 expression was also found in KCS subjects compared to
controls. Membrane bound MUC1 was present in higher concentration in SS versus NDE only. These significant changes
in MUC1 expression may represent compensatory or protective responses to chronic insult to the ocular surface.
Mucins constitute an important part of the preocular tear
film and ocular surface. It is believed that a large portion of
the tear film is a mucin/aqueous gel that decreases in density
from the epithelial surface toward the lipid layer [1,2] Mucins
participate  in  the  retention  of  water  and  other  tear  fluid
components  on  the  ocular  surface  and  thus  contribute  to
lubricity and healthy epithelia [3,4]. Our earliest information
about ocular mucins came from the study of goblet cells [5].
However, numerous studies have now shown that multiple
species  of  mucins,  including  transmembrane  mucins,  are
derived from the ocular surface epithelium [6-10].
Mucins are present on apical surfaces of all healthy wet
surface epithelia of the human body and on the glands of
simple  secretory  epithelial  tissue  [11,12].  Based  on  the
presence  of  common  structures  within  their  amino  acid
sequences, human mucins have been grouped together into
two main groups: secreted and transmembrane mucins [6,
13-20].
On the ocular surface, the large secreted gel-forming
mucin, human mucin 5AC (MUC5AC), is expressed by the
goblet cells and hydrates in the tear film to act as a lubricating
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agent and clearing molecule [21,22]. The membrane-tethered
mucins,  the  most  studied  of  which  are  human  mucin  1
(MUC1), human mucin 4 (MUC4), and human mucin 16
(MUC16), form the dense glycocalyx at the epithelial cell-tear
film interface [22] and serve to signal the cells to which they
are attached [23] and to provide protection [24]. MUC16 has
specifically been described as protecting the epithelium from
the penetration of clinical dyes such as rose bengal [25]. There
are also alternative soluble forms [25-29] of MUC1 [27] and
MUC16 [26,30] found in the tear film. These alternative forms
lack  the  cytoplasmic  tail  portion  of  the  protein  and  are
constituitively released into the tear film [11]. The functions
of these soluble portions of MUC1 and MUC16 are unknown.
Mucins have been implicated in the pathophysiology of
dry eye disease, but mucin deficiency is no longer described
as a separate class of dry eye [31]. According to the 2007
DEWS report, dry eye disease is now classified as aqueous-
deficient (AD) or evaporative (E) and within the AD dry eye
group, two major subclasses exist, Sjogren’s Syndrome (SS)
Dry Eye and Non-SS Dry Eye [31]. Dry eye research has
shown that the gel forming mucin MUC5AC, is a major factor
in dry eye disease in that its expression is reduced in dry eye
subjects [32]. However, more recent research is uncovering
the role of membrane spanning mucins in dry eye [24,33,34].
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1720It is the membrane spanning mucin MUC1 that is the
subject of this paper. MUC1 is the first human mucin to be
cloned  [35].  Its  functions  have  been  extensively  studied
because of its role in breast cancer [36,37]. MUC1 is the
shortest  [38]  of  the  transmembrane  mucins  of  the  ocular
surface. It is believed to contribute an anti-adhesive role that
has  been  well  studied  in  breast  cancer  [39].  Perhaps  this
property allows the lid to rub over the surface epithelium more
readily. The MUC1 cytoplasmic tail is believed to be a part of
many signaling events and this may allow the ocular surface
epithelium to respond to changes in the environment [40].
MUC1 is also believed to play a role in epithelial protection
from pathogens such as Pseudomonas aeruginosa [37].
In this study of MUC1 in dry eye disease, we characterize
the expression of MUC1 in Sjogren’s syndrome dry eye as
compared with aqueous deficient (KCS) dry eye and non dry-
eyed (NDE) controls, to gain further insight into the role that
MUC1 may play in dry eye disease.
METHODS
Study design: Prior to the start of this study, ethics approval
was  attained  from  the  Office  of  Research  Ethics  at  the
University of Waterloo and University Health Network in
Toronto and all procedures adhered to the Declaration of
Helsinki. A total of 76 subjects (26 non dry-eyed controls
[NDE], 25 Sjogren’s subjects [SS], and 25 non-Sjogren’s
keratoconjunctivitis [KCS]) were enrolled in this study. All
participants underwent a clinical evaluation visit to determine
entry eligibility before their second visit during which ocular
samples were collected.
The  inclusion  and  exclusion  of  subjects  has  been
described in a previous paper [30]. Briefly, all SS participants
had been diagnosed with primary SS at the multidisciplinary
Sjogren’s Syndrome Clinic of the Toronto Western Hospital,
using  the  American-European  consensus  criteria  of  2002
[41]. The KCS and NDE subjects were recruited through the
SS clinic and a private practice. KCS subjects had significant
symptoms of dryness for over 3 months and Schirmer scores
of ≤10mm in 5 min.
All subjects were free from allergy or other ocular surface
diseases  with  the  exception  of  blepharitis.  Subjects  with
blepharitis were allowed to use lid scrubs and hot soaks but
were not using topical antibiotics or topical anti-inflammatory
medication.
Reagents and materials: Gradient gels (NuPAGE® Novex
3%–8%  Tris-Acetate  Midi  Gel),  NuPage®  tank  buffer,
NuPAGE®  20×  transfer  buffer,  and  molecular  weight
standards  (Himark™)  were  purchased  from  Invitrogen
(Carlsbad,  CA).  The  transfer  unit,  Genie  Blotter,  was
purchased  from  Idea  Scientific  (Minneapolis,  MN).
Nitrocellulose membrane and blotting paper were purchased
from BioRad Laboratories (Mississauga, ON). NAP-Blocker
was purchased from G Biosciences (Maryland Heights, MO).
ECL-Plus™ kits were purchased from GE biosciences (Baie
d’Urfe,  QC).  DC  Protein  Assay  Kit  ®  and  nitrocellulose
membranes  were  purchased  from  BioRad  Laboratories.
Monoclonal mouse anti-human MUC1 antibody (DF3) was
purchased from Signet (#61401; Dedham, MA) and goat anti-
mouse IgG-HRP from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). MUC1 standard antigen (CA15–3) was purchased
from Calbiochem (San Diego, CA) Millipore™ Membrane
Filters were purchased from Millipore™ (Fisher Scientific,
Ottawa,  ON).  All  other  chemicals  were  purchased  from
Sigma-Aldrich (Oakville, ON).
Eye wash tear collection: The methods described below have
been described in detail in our previous paper [30]. Tears were
collected using an eye wash method based on a previously
described technique [32]. Briefly, 60 µl of sterile, physiologic
saline (0.9% NaCl; Minims, Chauvin Pharmaceuticals Ltd,
Romford,  Essex,  UK)  was  applied  to  the  superior  bulbar
region of the unanesthetized right eye, followed by the left,
and tears were collected from the inferior fornix using the
micropipette. The eye washes were pooled, vortexed briefly,
and placed on dry ice until transfer to −80 °C for storage.
Conjunctival  impression  cytology  (CIC):  Conjunctival
epithelial cells were collected via impression cytology from
each eye using sterile Millipore, MF membranes, (pore size
0.45 μM) [30]. Briefly, the right eye was anesthetized with
two  drops  of  a  topical  anesthetic  (Alcaine®;  Alcon,  Fort
Worth, TX). CIC was taken superiorly and temporally and the
membranes placed in 1 ml of RLT® RNA Isolation Buffer
(Qiagen,  Mississauga,  ON)  containing  0.01%  β-
mercaptoethanol. The same procedures were repeated on the
left eye and those two filter papers were placed in an empty
sterile tube, for subsequent protein extraction. All samples
were immediately placed on dry ice, then transferred to −80 °C
for storage until processing.
Protein isolation from CIC Samples:  Left eye impression
cytology  samples  were  used  to  isolate  total  protein  [30].
Briefly, filter papers were minced, then proteins extracted
twice  in  a  total  of  75  μl  extraction  solution  (2%  sodium
dodecyl sulfate; 1× Complete™ protease inhibitor cocktail
[Roche,  Mannheim,  Germany])  at  95  °C  for  10  min.
Aloquoted samples were stored at −80 °C until further use.
Determination of total protein concentration in tear and CIC
samples:  All  total  protein  determinations  were  conducted
using the DC Protein Assay Kit® following manufacture’s
instructions. Each of eye wash or impression cytology extract
(5 µl) was added to 5 µl of Milli-Q water and the final 10 µl
was divided equally between two microplate wells to allow
assay in duplicate.
Electrophoresis and immunoblotting: Samples were thawed
at  room  temperature  and  diluted  to  a  final  protein
concentration of 1 µg/μl with sample buffer (247 mM Tris-
HCl, pH 8.6, 2% SDS [w/v], 50 mM DTT, 1× Complete™
Protease  Inhibitor  [Roche],  10%  glycerol,  0.002%  [w/v]
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1721Bromophenol blue). Samples were heated at 100 °C for 3 min
before gel loading. A titration of MUC1 standard antigen
CA15–3 was run on each gel to normalize data and facilitate
semi-quantitation  of  samples,  through  linear  regression
analysis.  Following  separation,  protein  was
electrophoretically transferred to nitrocellulose membranes in
a 1/10 dilution of NuPAGE Transfer Buffer. Membranes were
fixed by heating at 70 °C for 30 min, air dried for 12 h then
blocked in PBS + 0.05% Tween-20 (=PBS-T) + 0.1% BSA +
10% NAP for 1 h at room temperature. Blots were incubated
overnight in mouse monoclonal antibody clone DF3, (1:40)
in PBS-T and 0.1% BSA + 10% NAP at 4 °C then with
secondary antibody (1:5000) in PBS-T + 0.1% BSA + 10%
NAP for 1 h at room temperature. Blots were developed with
ECL  Plus®  (BioRad)  and  chemiluminescent  signals  were
captured by Storm840® Imaging (Molecular Dynamics, Baie
d’Urfe,  QC).  The  amount  of  MUC1  in  each  sample  and
standard  were  quantified  by  image  analysis  software
(ImageQuant 5.1®; Molecular Dynamics). Known amounts
of CA15–3 standard were used to generate standard curves
and using the line-of-best-fit from the standard curve, the
relative amount of mucin in the samples was interpolated from
the graph. As multiple bands were generated in mucin western
blots for all samples, all bands of 325 kDa and greater were
used  to  quantify  expression.  Bands  below  325  kDa  were
ignored.
RNA isolation from CIC samples and reverse transcription:
Tubes containing 1 ml of RLT® buffer (Qiagen) and two
impression cytology samples were allowed to thaw at room
temperature then vortexed. Membranes were removed using
a 21 guage needle and samples were passed through a 21
gauge needle 10 times. Extraction of total RNA proceeded
according to manufacturer’s directions (RNeasy® Minikit;
Qiagen). The final isolation step was conducted with 40µl of
RNase free water.
cDNA was synthesized from 8 µl of RNA sample using
random hexamer primers with Superscript™ III First-Strand
Synthesis System for RT–PCR (Invitrogen) according to the
manufacturer’s instruction.
Real Time-qPCR: Multiplex PCR reactions containing target
(MUC1) and endogenous control (GAPDH) oligonucleotide
primers were performed in the presence of gene-specific dye-
labeled Taqman probes (Table 1). Briefly, 2 μl of cDNA were
used for amplification in a 50 µl PCR reaction containing
target  and  endogenous  control  oligonucleotide  primers,
control and target Taqman probes and Taqman® Universal
PCR Master Mix . Duplicate samples were used for analysis
in  a  7500  Real  Time  PCR  System  (Applied  Biosystems,
Carlsbad, CA). Conditions used for amplification were as
described in our previous paper [30]. Normalized reporter dye
fluorescence (Rn) data was collected during the extension step
at  each  cycle.  Collected  data  was  analyzed  and  fold-
expression changes were calculated using the comparative
method (2-ΔΔCT) of relative quantification by SDS software
(v1.3.1; Applied Biosystems).
Data  analysis:  Statistical  analysis  was  performed  using
Statistica  Ver7.1  (StatSoft  Inc.,  Tulsa,  OK,  USA)  and
Microsoft  Excel™  XLfit©  (IDBS,  Surrey,  UK)  software.
Graphs were plotted using Statistica Ver7 (StatSoft, Tulsa,
OK).1. All data are reported as mean ±standard deviation.
Statistical  differences  between  groups  for  biomarker  data
were  identified  by  using  one-way  ANOVA,  and  when
necessary, Dunnett’s comparison of means and by Tukey’s
test. Significance was identified at p<0.05 (α=0.05).
RESULTS
Demographics and tear flow measurements: A total of 76
subjects were enrolled into this study. The demographics of
these subjects are displayed in Table 2.
The mean age of the SS group was found to be statistically
higher than the NDE group (p=0.024), but not different from
the KCS group (p>0.05). Mean Schirmer I scores from both
eyes  collected  without  anesthesia  for  5  min  revealed  a
significantly  reduced  (p<0.0001)  tear  flow  in  both  SS
(5.12±5.96 mm) and KCS subjects (7.84±7.35 mm), relative
TABLE 1. SEQUENCE DATA FOR GENE AMPLIFICATION IN REAL TIME RT–PCR.
Gene Forward primer Reverse primer Taqman probe
MUC1 CTGGTCTGTGTTCTGGTTGC CCACTGCTGGGTTTGTGTAA 6FAM-GAAAGAACTACGGGCAGCTG
GAPDH GAAGGTGAAGGTCGGAGTCA GACAAGCTTCCCGTTCTGAG VIC-CAATGACCCCTTCATTGACC







Control group of non dry-eyed 52.4±11.4 24 2 26
KCS 59.3±9.1 21 4 25
Sjogren’s syndrome 60±11.8* 21 4 25
        The asterisk denotes significantly greater compared to control group (p=0.024).
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1722to NDE (23.83±7.85 mm). There was no difference in mean
Schirmer I scores between the KCS and SS groups (p=0.19).
Comparisons:  Two  of  the  25  SS  subjects  did  not  supply
sufficient tear samples for analysis of soluble MUC1, limiting
this  analysis  to  23  of  the  25  SS  subjects.  The  SS  group
expressed  a  significantly  higher  concentration  of  soluble
MUC1 compared to both KCS (0.14±0.15 [SS]; 0.013±0.02
[KCS]; p=0.001) and NDE (0.0023±0.0024; p<0.001) groups
(Figure  1  and  Figure  2).  The  SS  group  also  expressed  a
significantly higher concentration of MUC1 mRNA compared
to both KCS (3.18±1.44 [SS]; 1.79±1.18 [KCS]; p<0.05) and
NDE (1.60±0.75 [NDE]; p<0.05) groups (Figure 3). The KCS
group  expressed  a  significantly  greater  concentration  of
soluble MUC1 compared to the NDE group (p=0.02). Lastly,
the  only  significant  difference  found  in  membrane  bound
MUC1  expression  was  between  the  SS  and  NDE  groups
(0.005±0.003 [SS]; 0.003±0.002 [NDE]; p=0.002; Figure 4),
with the SS group demonstrating more membrane MUC1 than
the NDE group.
Figure 1. Western blot and regression analysis for soluble MUC1
quantification A: Examples of Soluble MUC1 western blots from
tear samples derived from Normal, KCS, and SS and subjects. Lanes
1–6 are MUC1 standard antigen (CA15–3) Units; (Lane 1=0.3, Lane
2=0.1, Lane 3=0.06, Lane 4=0.03, Lane 5=0.01, Lane 6=0.003 U);
Lanes 7–13 are examples of tear samples from Normal, Lanes 14–
20 are from KCS, and Lanes 21–26 are from SS. B: A regression
curve was created by graphing applied concentration of CA15–3
standard  against  the  optical  density  of  the  resulting  band
immunoreactivity. Total MUC1 concentration was quantified by
interpolation from this curve. MW standard (460) is listed on the left.
DISCUSSION
The  results  of  this  study  demonstrate  that  subjects  with
confirmed  Sjogren’s  syndrome  have  increased  levels  of
soluble MUC1 in their tear film and MUC1 mRNA in their
conjunctival epithelial cells compared to both KCS and non
dry eye (NDE) subjects and that SS subjects have increased
levels of membrane bound MUC1 compared to NDE subjects.
KCS subjects demonstrated increased levels of soluble MUC1
compared to NDE. To our knowledge, this is the first time that
soluble MUC1 concentrations have been compared in these
groups.
We note that age may have been a factor in our results,
as the mean age of the two dry-eyed populations was greater
compared to the control group, with significance reached in
the  SS  group.  It  is  known  that  tear  volume,  production,
stability and /or quality is reduced in the older population
[42,43], but age factors have not been determined for the status
of mucin on the ocular surface. We feel that our results are
Figure  2.  Soluble  MUC1  expression  as  quantified  by  western
blotting. Data expressed as (A) scatter graph of individual data points
and (B) mean data. Protein samples collected via eye wash and
MUC1  data  expressed  in  Units/μg  protein  as  calculated  from
interpolation from a standard curve titration of CA15–3. The asterisk
indicates significantly different compared to NDE Group. The sharp
(hash  mark)  indicates  significantly  different  compared  to  KCS
Group.
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1723relevant however, as in our study there was no significant age
difference between the KCS and SS groups, while there were
significant findings in mucin expression.
The authors are aware that dry eye disease is generally
believed to be a disease of reduced mucin secretions. This has
been  demonstrated  most  consistently  with  the  findings  of
reduced  secreted  MUC5AC  in  the  tears  of  Sjogren’s
syndrome patients [32], and in their conjunctival cells [32,
44] compared to normals. KCS subjects also showed reduced
MUC5AC in tears and conjunctival cells compared to normals
in 3 studies [32,44,45]. One study by Zhao et al. [46] found
no difference in MUC5AC levels in the tears of KCS subjects
versus normals.
Figure 3. Expression of MUC1 mRNA in conjunctival epithelial
cells. RNA isolated from conjunctival epithelial cells collected via
impression cytology. The asterisk indicates significantly different
compared to the NDE Group and the sharp (hash mark) indicates
significantly different compared to the KCS Group.
Figure  4.  Membrane  bound  MUC1  expression  as  quantified  by
western blotting. Protein samples collected via impression cytology.
MUC1  data  expressed  in  Units/μg  protein  as  calculated  from
interpolation from a standard curve made from titration of CA15–3.
The asterisk indicates significantly different compared to the NDE
Group.
Very little has been written comparing transmembrane
mucins in these groups. Danjo et al. [33], using histochemical
staining of surface conjunctival epithelial cells gathered from
impression cytology, noted reduced expression of MUC16 in
non-SS dry eye and observed that this was associated with
rose bengal staining. Data on other membrane bound mucins
has  suggested  that  the  expression  of  mucosal  epithelial
membrane mucin (as detected by an uncharacterized antibody
referred to as AMEM2), is reduced in SS and non-SS dry eyed
subjects compared to normals [47].
These observations stand in contrast to our results that
demonstrated no difference in membrane bound MUC1 in the
conjunctiva of SS subjects compared to aqueous deficient dry
eye and increased expression compared to normal subjects
[30]. Our methods are certainly different as they involved cells
from one eye that were pooled after collection from both
temporal  (exposed)  and  superior  bulbar  conjunctiva  as
opposed to temporal cells that were analyzed by Danjo et al.
[33]. Also our testing was completed by western blot analysis.
It is possible that the vagaries of glycosylation of these mucins
in  dry  eye  disease  would  hinder  their  detection  using
histochemical  staining  techniques.  This  inability  to  detect
membrane bound MUC1 because of glycosylation differences
is documented in the literature where the presence of MUC1
on hematopoietic cells in patients having certain cancers was
ignored for some time [27].
An  association  between  reduced  membrane  bound
mucins, specifically MUC16, and the presence of rose bengal
staining has been suggested by Danjo et al. [33] in human
cells,  and  Argueso  et  al.  [25]  in  human  corneal-limbal
epithelial cells lines (HCLE). If all transmembrane mucins are
involved in resisting rose bengal penetration, then these data
conflict in principle with our findings of increased levels of
membrane bound MUC1 in SS versus NDE and no difference
in membrane bound MUC16 in our previous work with SS,
KCS  and  NDE  [30],  since  rose  bengal  staining  is  found
clinically in greater amounts in Sjogren’s syndrome patients
[48]. Recent work by Argueso et al. [49], however, suggests
that, in vitro, it is the interaction of the carbohydrate binding
protein  galectin-3  with  the  carbohydrate  portion  of  both
MUC1 and MUC16 that creates a protective barrier to the
penetration  of  dye  such  as  rose  bengal.  Therefore,  the
concentration of membrane bound mucins may not be the
issue but rather their ability to interact with galectin-3.
The concentration of mRNA of transmembrane mucins
in the conjunctival epithelium has been studied by others,
albeit rarely. At the genetic level, a specific splice-variant of
the MUC1 gene was found to be slightly reduced in dry eyed
subjects [50]. In contrast, other authors have failed to find
differences  in  MUC1  or  MUC4  gene  expression  between
controls and SS subjects [32]. To our knowledge, this is the
first time that mRNA levels in human conjunctival epithelial
cells have been compared in these three groups.
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1724These results, combined with our previous work with
MUC16  [30],  demonstrate  an  excess  of  both  MUC1  and
MUC16 in the tear film of SS subjects and increased levels of
mRNA for these mucins in conjunctival cells. The finding of
increased tear mucins in SS is of particular interest to the
clinical author (B.C.) of this study as the observation of excess
mucus in the tears of SS patients is a long standing clinical
finding  in  her  experience.  Mechanistically,  albeit
simplistically, it appears that increased expression of mRNAs
coding  for  MUC1  and  MUC16  are  followed  by  excess
shedding of these species into the tear film, or vice versa. The
excess expression of mucins in disease states is a well studied
phenomenon. In fact, excess mucin production in humans is
an ancient defense mechanism [51] and non-ocular mucous
membranes  demonstrate  excess  mucus  production  under
adverse conditions in dogs, rats, and humans [52-54]. Excess
mucin of the ocular surface occurs most commonly in ocular
allergy and here there is excess of transmembrane MUC1,
MUC4, and MUC16 [55]. In vitro, inflammatory mediators
that have been found in the tear film of dry eye patients have
been shown to increase MUC1 expression in a human limbal
corneal  epithelial  cell  line  [23].  Also,  ocular  cicatricial
pemphigoid  (OCP)  patients  demonstrate  increased  mucin
production [56]. This increased mucin activity in the early
stages of the keratinisation process, or during inflammation,
suggests  that  ocular  surface  cells  can  participate  in
compensatory attempts to synthesize more mucin to maintain
a wet surface phenotype or to protect themselves in other
ways.
The shedding of the extra cellular portion of MUC1 has
been studied in infection and is considered to be a reaction of
the molecule to changes in its environment that then signals
the cell to which it is attached [37]. It is suggested that the
release  of  the  extracellular  portion  produces  “activation,
proliferation or apoptotic response” of the epithelium [37].
Perhaps this exposed portion of MUC1 is shed because of
physiologic changes associated with severe dry eye disease
and this activity then signals the epithelial cells to produce
more  MUC1.  Our  findings  would  suggest  that  this
compensatory or protective mechanism is most prevalent in
SS dry eye disease, but may be related to disease severity, as
suggested  by  the  increased  soluble  MUC1  seen  in  KCS
subjects  over  NDE  subjects  in  our  results.  To  probe  this
hypothesis, additional work is required with severe non-SS
dry eye patients.
In  summary,  we  quantified  the  expressions  of  ocular
surface MUC1 in Sjogren’s subjects and compared them with
non-Sjogren’s dry-eyed subjects and non-dry eyed controls.
We  found  that  Sjogren’s  subjects  express  significantly
elevated concentrations of both soluble MUC1 and MUC1
mRNA compared to both KCS and NDE groups. The KCS
group also demonstrated increased concentrations of soluble
MUC1 in the tear film compared with NDE subjects. We
propose that the conjunctival epithelium of Sjogren’s subjects
reacts to dry eye changes in the tear film that cause increased
shedding of MUC1 and increased production of this molecule
in an attempt to protect the ocular surface and to maintain a
healthy surface phenotype.
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